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                                       : Biodegradable Poly(caprolactone fumarate) (PCLF) 
has been used as bioresorbable sutures. In this study, doxorubicin HCl (Dox) loaded PCLF 
nanoparticles were prepared and characterized.
                      PCLFs were synthesized by polycondensation of PCL diols (Mws of 
530, 1250 and 2000) with fumaryl chloride. The degradation of PCLF in NaOH, water and 
phosphate buffer saline (PBS), was determined in terms of changes in Mw. Nanoparticles (NPs) 
were prepared by two methods. In microemulsion polymerization method, dichloromethane 
containing PCLF and photoinitiator were combined with the water containing surfactants 
and then the mixture was placed under light for crosslinking. In nanoprecipitation method, 
the organic solvent containing PCLF was poured into the stirring water. The effect of several 
variables including concentration of PCLF, polyvinyl alcohol (PVA), Dox and Trypan blue 
(Trb) and the Mw of PCLF and PVA on NP size and loading were evaluated.
         PCLF 530, 1250 and 2000 in PBS or water were not degraded over 28 days. 
Nanoprecipitaion method gave spherical (revealed by SEM images) stable NPs of about 
225 with narrow size distribution and a zeta potential of -43 mV. The size of NP increased 
                                                                                        
for formation of NPs, but it decreased with NP size. Dox loading and EE were 2.5-6.8% and 
15-20%, respectively. Increasing the drug concentration increased the drug loading (DL) and 
                                                                                    
PCLF2000. An increase in PCLF concentration resulted in an increase in EE. Dox and Trb 
release  showed  a  burst  followed  by  80%  and  78%  release  during  3  and  4  days  respectively.                                                                                       
            PCLF possessed suitable characteristics for preparation of nanoparticulate drug 
delivery system such as desired NP size, stability and degradation time. Although PCLF530 NPs 
were the smallest, but their DL were lower than PCLF1250 and 2000 NPs. 
          PCLF nanoparticles, Copolymer molecular weight, Nanoprecipitation method.
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Polymers and polymeric NPs are promising vehicles 
for drug delivery. Their important properties are easy 
manipulation to prepare carriers with the objective 
                                                    
an advantage improves the drug safety (1) which is 
particularly important for cancer therapy by reducing 
wide side effects of the anticancer drugs. One way to 
achieve this goal is the passive targeting of the active 
molecules to the tumor site, which is mainly based on 
the enhanced permeability and retention (EPR) effect. 
It means that the polymeric NPs in comparison with 
the free drugs are accumulated in the tumor tissues 
more than normal tissues due to high permeability 
and low drug elimination related to tumor sites. 
Moreover, NPs can prolong blood circulation time 
and control the release rates of drugs in tissues 
(2,3). Poly (caprolactone) (PCL) is a hydrophobic 
biocompatible and biodegradable polyester which 
has been used for bioresorbable sutures and 
scaffolds (4) and for micro and nanoparticulate drug 
delivery systems (3,5). PCL biodegradability can 
12be improved by proper copolymerization strategies 
(6,7). Several copolymers have been synthesized 
from PCL and a hydrophilic segment such as poly 
(ethylene glycol) (PEG) (8,9). Hydrophilic fumaric 
acid has been utilized by Shin et al to synthesize oligo 
(PEG fumarate) (OPF) for hydrogel implants by 
crosslinking the double bond of fumarate. Grijpma et 
al have reported synthesize of star-shaped oligomers 
functionalized with fumaric acid monoethyl ester 
(FAME) and preparation of networks by its photo-
crosslinking (10,11). Wang et al copolymerized 
fumarate with PCL as poly(caprolactone fumarate) 
(PCLF, Fig 1) copolymers and used it to prepare 
implants for tissue engineering. 
Since particulate systems of PCLF have not been 
reported, in this study, synthesis of PCLF according 
to Wang et al (12,13) and its uses for preparation of 
NPs suitable for drug delivery was investigated. In 
addition, since macrophages in reticuloendothelial 
system (RES) tend to phagocyte more hydrophobic 
molecules, it seemed that  hydrophobic PCLF NPs 
can enhance lymphatic uptake and to be useful for 
lymphoma therapy by passive targeting (14,15). The 
hydrophobicity of PCLF can be easily tunable via 
synthetic process by using precursors of different 
Mws and probably PCLF may encapsulate more 
hydrophilic drugs in comparison with simple PCL. 
Self-crosslinkable PCLF may adjust drug loading 
and release of the NPs (16). Myocet and Doxil 
are liposomal dosage forms of doxorubicin HCl 
(Dox) with reduced cardiovascular side effects. 
In this study, Dox loaded NPs were prepared by 
nanoprecipitation method and then prepared as 
sterile NPs powder for stable NPs aqueous solution 
for intravenous administration.
                    
Doxorubicin HCl (Dox), fumaryl chloride, PCL 
diols (nominal number-average molecular weight, 
Mn of 530, 1250 and 2000 g mol-1), poly vinyl 
alcohol (PVA) (weight average molecular weight 
(Mw) of 22000 and 72000 g mol-1),  N Vinyl 
Pyrrolidone  (NVP), polysorbates 80 and 20 and 
dermaphyl were purchased from Sigma-Aldrich Co. 
(USA) trypan blue (Trb), K2CO3, dichloromethane 
(DCM), acetone, methyl methacrylate (MMA), 
camphorquinon (CQ) and other chemicals were 
of synthetic grades and purchased from Merck 
(Germany).
        
                                           
          
PCLF530, PCLF1250 and PCLF2000 (named 
after their precursors) were synthesized through a 
polycondensation reaction according to the reported 
method (12,13) using PCL diols with Mw of 530, 
1250 and 2000 g mol-1, fumaryl chloride and K2CO3 
                                     1H-NMR and 
FTIR. PCLF Mw and melting point (Tm) were 
determined by Gel Permeation Chromatography 
(GPC) and Differential Scanning Calorimetry (DSC) 
spectra , respectively according to the previously 
reported method (18). The 1H-NMR spectra of 
copolymers were recorded on a Bruker 500 MHz or 
Varian Unity Plus 400 (300 MHz) or a Bruker 80 
MHz spectrometers using DMSO-d6 as solvent. 
IR spectra were obtained using a Nicolet FT-IR 
Magna 550 spectrophotometer. The GPC device 
was from Knauer Co., with refractive index detector 
2300, and the used column was Knauer AXX10 
column, 1510-5330 PKL gel mixed E 3μm 250x4 
6mm. A calibration curve constructed by a series of 
polystyrene standard using THF as eluant, was used 
to estimate the Mw of copolymers. DSC scans were 
obtained by a Mettler DSC 823 (Mettler Toledo 
GmbH, Switzerland) with Mettler Star® Software, 
Version 9.x. PCLF.
For in vitro degradation test, 30 mg of the sieved 
powder of PCLF2000 was immersed in 30 ml 
of different media in sealed glass tubes at 37°C. 
PCLF and medium samples were taken at certain 
time intervals and the PCLF Mw and fumaric 
acid concentration were measured using GPC 
method (19) and UV spectrophotometer at 207 nm, 
respectively.
                                             
                                   
Two ml of DCM and/or MMA as organic solvent 
containing PCLF (0.5-1 w/v%) and CQ (crosslinking 
photo-initiator) (0.005 w/v%) was poured into 50 ml 
of the solution of dermaphyl as surfactant in water 
(4-24% v/v) with or without polysorbates 80 and 20 
(5-15% v/v) under stirring, and placed under visible 
light for one hour.
                         (20)
Two milliliters of a solution of PCLF in acetone 
(0.1-6% w/v) was poured into 4 ml of water solution 
of PVA (0.01-0.6% w/v) and drug (0.02-0.4% w/v) 
under stirring. The resulting NPs suspension was 
                                                       
                                                 
Whatman). NPs were washed by DW and then 
redispersed in DW to check their stability. NPs 
suspension was lyophilized (Lyotrap plus freeze 
                                                 
          Chemical structure of PCLF.
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ready for re-dispersion in water.
The effects of several variables including the 
concentration of the components, Mw of PCL 
diol and PVA (22000 and 72000 g/mol), type of 
the solvent (S) or non-solvent (NS) and the S/NS 
ratio (0.02-1) as well as some process parameters 
on NP size, polydispersity index (PDI), zeta 
potential (laser light scattering, PCS, Malvern 
Zetasizer, Nano-ZS series, Malvern Co., UK) 
and drug loading (DL) were investigated. Each   
variable was changed while others were constant. 
The NPs size, shape and surface morphology were 
checked by Scanning Electron Microscopy (SEM, 
Philips XL 30 scanning microscope, Philips Co., 
the Netherlands). SEM samples were prepared 
by dropping 200 μl of each NP suspension onto a 
standard glass surface and removal of water under 
reduced pressure. 
                                              
calculated as follows:
EE (%) =
Amount of drug in NPs
  100
Total amount of drug
 
DL (%) =
Amount of drug in NPs
  100
Amount of drug-loaded NPs
The amount of drug in NPs was determined by 
subtraction of the unloaded drug from the total drug 
that initially was added to the solution. The unloaded 
drug concentration, was measured by UV/VS (Jasco 
V-530, Jasco co., Japan) absorbance at 586 and 233 
nm for Trb and Dox, respectively after separation of 
                   
NPs suspended in DW, were tested for size at room 
temperature (RT) at certain time intervals without 
considering the precipitates (if any).
For the drug release experiments, 12 mg of 
lyophilized NPs (formulations 15 or 21, Table 4) 
was suspended in a 10 ml of DW loaded in a dialysis 
bag and placed in 30 ml of PBS and then positioned 
on a shaker incubator (Heidolph incubator 1000, 
Heidolph co., Germany) at 37°C and 70 rpm. At 
selected time intervals, 5 ml samples were taken and 
replaced with 5 ml of fresh PBS.
                    
The data were presented as mean ± SD. One-
way analysis of variance (ANOVA) was used for 
comparing the mean differences. SPSS for Windows 
(release 11.5.0) was employed for statistical analyses 
                                                 
experiments were performed in triplicates, and the 
averages values were taken into considerations.
                      
                                       
The 1H-NMR, FTIR, GPC and DSC spectra data of 
PCLFs were in accordance with the reported data by 
Wang et al (12). The Mw, PDI and Tm of the PCL 
diols and PCLFs are given in table 1. The number 
of oligomers joined with fumarates to form PCLF, 
were 4.9, 2.3, and 1.8 for PCLF530, PCLF1250 
and PCLF2000, respectively, due to the differences 
in the reactivities of used PCL diols (12). Yield 
of copolymerization (weight of copolymer after 
                                                 
90-95% which decreased at temperature below 50°C. 
PCLF530 did not reveal Tm because of its semisolid 
state. The Tm of PCLF2000 and PCLF1250 were 
slightly higher than the Tm  of  their  macromonomers.     
PCLF Mw (11000-12000) did not change 
                                                       
acetone, PBS of pH 7.4, DW and 1N NaOH 
(p>0.05) (Fig 2), then decreased slightly in PBS and 
water and dramatically in NaOH indicating partial 
and complete degradation. Data analysis using 
ANOVA model showed that the change in Mw in 
                                                  
                                                  
Decreased Mw in buffer solution compared with 
water as medium was higher, indicating the role of 
ions in degradation of PCLF. The amount of fumaric 
acid released from PCLF (Fig 3) was consistence 
with the presses of its degradation (Fig 2). 
                                                    
the primary and the ultimate Mw in PBS and water 
over one month (P>0.05). Thus the degradation 
of the PCLF is slow (in comparison with other 
Macromer polymer   Mn (g/mol)        MW (g/mol)       PDI Tm (°C)
PCL diol 530 792 1218 1.5 ___
PCL diol 1250 2844 4010 1.2 60
PCL diol 2000 3092 6339 2.0 63
PCLF530 4019 6026 1.4 ___
PCLF1250 6960 9287 1.3 57
PCLF2000 8455 11623 1.3 59
Mn                                     W                                                               m  , melting point.
         physical characteristics of PCL diols and PCLFs. Shokri et al / DARU 2011 19 (1) 12-22 15
PBS
water
NaOH
polyesters) enough to show a sustained release of 
drug (21,22) which is related to its synthetic origin 
(23). Moreover PCLF exhibits a high level of 
hydrophobicity (22) which may inhibit the access 
of water to the polymer during the degrardation (24, 
25).
                                   
Experiments revealed that by this method, 
formation of NPs was highly dependent on the 
exact concentrations of the used materials. It has 
also been reported that the size of NPs produced   
                                                  
of the polymerizing mixture especially the type 
                                                   
Most of the produced NPs were unstable in their 
aqueous suspension, aggregate and precipitate 
after a few hours to one day. Among many 
prepared formulations by different concentrations 
of copolymer or surfactant, different types of 
surfactants and different S/NS ratios, few of them 
remained stable as suspension during a few days 
indicating slower aggregation. Such formulation 
of NPs were made by addition of 0.2 ml MMA 
containing CQ and PCLF2000 (1% w/v) into 50 ml 
of dermaphyl (10% in DW), representing NP size 
of 191.7±40.3 nm, PDI of 0.27 and zeta potential 
of -23.4±10.7 mV. Also another formulation 
PBS
water
NaOH
          Cumulative percentage of the released fumaric acid from PCLF2000 in different mediums during 28 days (n=3).
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          Change of PCLF2000 Mw, in different mediums during 28 days (n=3).
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composed of 2 ml of MMA containing CQ 
PCLF2000 (1 w/v%), and 50 ml DW containing 
10% dermaphyl and 10% polysorbate20, had 
NP size of 403.1±67.8 nm and, PDI of 1.0±0.3. 
NPs prepared by this method showed decrease 
in diameter by increase in concentration of 
                                                  
                                                  
as the surfactant to prepare PEG-PPG-PEG NPs by 
inverse emulsion polymerization method (17). By 
increasing the copolymer concentration above 1%, 
the particles were large and resulting suspension 
was unstable and precipited.
                        
In this method, NPs were produced immediately and 
                                                 
by nanosizer Malvern Co. (UK), and on the contrary 
of the microemulsion polymerization method, 
produced NPs over a wider range of concentrations 
of the compositions and different ratios of solvents. 
                                                 
for different purposes. Moreover, this method 
resulted in more re-dispersable and more stable 
NPs than other method. In addition, the number 
of materials which were used in this method and 
their toxicities were lower than the microemulsion 
polymerization method which was consistent with 
results of another report (26). Additionally the use 
of PVA was not necessary for NPs formation in this 
method (formulation 6, Table 2), which is important 
for intravascular delivery. The lower PDI and SD of 
NP size obtained by repeated formulations of this 
method (0.1 and 7.8 respectively for formulation 
8), than the microemulsion polymerization method 
(0.27 and 40 respectively), demonstrated a higher 
reproducibility of the nanoprecipitation method and 
a narrow distribution pattern of the NPs (Fig 4), 
                                                      
this method was chosen to investigate preparation 
and characterization of PCLF NPs. Table 2 shows 
when the solvent and non-solvent are acetone and 
DW, respectively, the NPs size was 117-216 nm 
(formulation 6-13). The negative zeta potential of 
the NPs was probably due to the residual carboxylic 
acid groups of the fumaric acid terminated polymers, 
as for the PLGA. Control formulation (formulation 
8 without PCLF) produced NPs with sizes of 
318.1±11.0 nm, PDI of 0.5±0.0 and zeta potentials of 
-1±0.4 mV. Therefore such a formulation may be just 
clusters of PVA molecules. A solution of PCLF in 
acetone and a water solution of PVA, both exhibited 
                                                    
                                
                                                 
As listed in table 2 (formulation 1-6), the NP size was 
                                                 
data obtained by other investigations where the 
use solvents with low dielectric constant or non-
                                                    
DW as non-solvent (formulations 1, 2, 3 and 8), and 
acetone produced the smallest NPs (formulation 8) 
and DMSO gave the largest NPs (formulation 1) 
which might be due to the rapid diffusion of acetone 
into DW (27). Therefore acetone was chosen as 
the solvent. Although NPs made by NVP were the 
smallest, but this solvent was not selected because 
of its toxicity in comparison with the acetone. By 
using PBS as non-solvent, increase in the NP size 
(comparing formulations 8 and 4) resulted in a 
complete precipitation after one day which might 
be due to the ionic interactions. Although using 
ethanol as non-solvent as reported by Bilati et al, 
produced PLGA NPs of 50 nm which were larger 
than water produced NPs (26), using ethanol in 
this study (formulation 5), resulted in NP size and 
zeta potential almost the same as formulation 8. 
Therefore DW was preferred to use as non-solvent 
and formulation 8 was chosen as the reference for 
other formulations in the article.
                                              
Formation of NPs in the absence of PVA (formulation 
6) revealed that PVA is not a required component 
for nanoprecipitation method (Table 2). The size of 
NPs prepared in the presence of PVA (formulations 
7 and 8) were smaller than those without PVA 
(formulation 6). Moreover, PVA22000 seemed to be 
more effective to form small NPs than PVA72000 
apparently due its lower Mw (formulations 7 and 
8). There was no considerable difference in PDI of 
all these three formulations. Therefore PVA22000 
was used for all formulations. The effects of the 
PVA22000 concentration in DW on the NP size are 
                                                 
increased, the NP size was decreased reaching to a 
mean size of 136.8±11.0 nm at PVA concentration 
of 0.15 w/v%, after which NP size increased by 
increasing the PVA concentration (28).
Results for formulations of 8-13 in table 2 reveal that 
higher the Mw of the PCLF, larger will be the related 
NPs. By using a certain concentration of PCLF, it 
was found that PCLF2000 and 1250 produced NPs 
larger than PCLF530 (compare formulations 8, 10 
and 12, or formulations 9, 11 and 13) (26). Consistent 
                                                    
study showed that the size became larger when 
concentration of PCLF in acetone was higher. Figure 
6 shows that the NP size was increased dramatically 
by increase in PCLF2000 concentration. Figure 7 
shows that the zeta potential decreased (becoming 
more negative) when the PCLF2000 concentrations 
decreased which may be attributed to the increase in 
the density of charge for smaller particles.
SEM images (Fig 8) demonstrated the spherical 
shape of the NPs with a relatively monodispersed 
size distribution which were in agreement with Shokri et al / DARU 2011 19 (1) 12-22 17
          Size distribution of the NPs by intensity.
          Variation of the size of the NPs (formulation 8) prepared by using different concentrations of PVA22000 in DW (n=3).
          Variations of the size of the NPs (formulation 8) prepared by different concentrations of PCLF2000 in acetone (n=3). The error 
bars of NP sizes are smaller than symbols.
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          Variation of the size of NPs (formulation 8) prepared by using different S/NS ratios (n=3).
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Formulation No. Solvent  Non-solvent
PCLF Mw and  
concentration (w/v%)
PVA Mw and 
concentration (w/v%)
NP Size±SD (nm) PDI Zeta potential (mV)
1 DMSO DW 2000,0.03 22000,0.3 364.9±23.6 0.3±0.0 -9.1±2.1
2 Methanol DW 2000,0.03 22000,0.3 223.5±17.3 0.1±0.0 -14.5±9.3
3 NVP DW 2000,0.6 22000,0.3 110.3±3.4 0.1±0.0 -17.9±7.6
4 Acetone PBS 2000,0.6 22000,0.3 211.5±5.6 0.1±0.0 -33.2±17.1
5 Acetone Ethanol 2000,0.6 22000,0.3 175.0±9.8 0.0±0.0 -35.6±9.4
6 Acetone DW 2000,0.6 - 204.3±11.7   0.1±0.0 -44.5±9.5
7 Acetone DW 2000,0.6 72000,0.3 197.0±4.3 0.1±0.0 -33.1±7.2
8 Acetone DW 2000,0.6 22000,0.3 173.0±7.8 0.1±0.0 -31.9±5.7
9 Acetone DW 2000,1 22000,0.3 216.3±19.2 0.1±0.0 -28.9±9.0
10 Acetone DW 1250,0.6 22000,0.3 176.0±7.2 0.1±0.0 -28.1±3.2
11 Acetone DW 1250,1 22000,0.3 185.9±29.2 0.1±0.0 -32.2±6.6
12 Acetone DW 530,0.6 22000,0.3 117.3±10.1 0.1±0.0 -52.7±4.3
13 Acetone DW 530,1 22000,0.3 129.3±15.3 0.1±0.0
-32.1±3.9
                                                                                                
         Size, PDI and zeta potential of unloaded NPs prepared by different formulations. The S/NS ratio for all formulations was 1:2 
(n=3).
A: stirring rate (rpm) B: stirring time (min)  C: Rate of the addition of acetone
120 720 0 20     Slow Fast
NP size (nm) 175.6±15.9 149±6.5 172 ±9.1 185±13.2 198.6±22 163±7.2
PDI 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0 0.1±0.0          
                                                                                                                                          
and 20 minutes stirring after preparation, C: Dropwise addition (slow) and immediate addition (fast) of two phases (n=3)
                                                  
difference in the morphology was observed between 
NPs of PCLF 530, 1250 and 2000, although they had 
different sizes (Figs 8. A, B and C).
                                               
Figure 9 shows that the NP size did not change 
dramatically by increase in S/NS ratio (where other 
variables were selected the same as formulation 8), 
with an optimum ratio of 1:4 producing smallest NPs 
(141.2±11.9 nm). Similar results have been reported 
for formation of PLGA NPs (26).
As it may be found from table 3, smaller NPs 
were produced at high stirring rate (720 rpm) and 
                                                   
                                               
phases were added slowly or in a dropwise manner, 
resulting NPs were larger than when the phases were 
added quickly or immediately, however difference 
in size of NP between these two methods, was not 
                                  
                                     
NP size increased by increase in the initial 
concentration of Trb in DW (Fig 10). NPs prepared 
without PVA, were larger than those prepared with 
PVA22000. This phenomenon was not observed 
for the formulations using Trb at concentrations 
of about 0.05 or higher, probably because of the 
lower ability of PVA to reduce the NP size in the 
presence of high concentrations of Trb. According 
to table 4, when Trb concentration was 0.1% w/v, 
the NP size was 205.9±9.0 nm, zeta potential was 
-41.7±11.1 mV and DL and EE were 0.99±0.21 
and 5.94±1.0, respectively (formulation 15) which 
in comparison with formulation 8, reveals a 20% 
increase in size after loading of Trb. A Comparison 
of formulations 20 and 21 with 8, reveals a 30 
and 50% increase in the size respectively after 
loading of Dox. Such increase might indicate the 
entrapment of drug molecules in the NPs (30) but 
it could also arise from aggregation of the NPs. 
Zeta potential decreased after loading of the Trb 
or Dox, (formulations 14 to 21, table 4, compared 
with the unloaded NPs of formulation 8, table 2) 
which may be attributed to accumulation of drug 
molecules at NP surface. DL of Dox or Trb were 
quite low (increased by drug concentration), which Poly (caprolactone fumarate) nanoparticles containing doxorubicin HCl 20
Formulation No.
PCLF Mw & 
concentration  (w/v%)
Drug concentration 
(w/v%)
NP size (nm) Zeta potential (mV) DL (w/w%) EE (w/w%)
                                                                                            Trb
14 2000, 0.6 0.02 179.0±3.1 -35.2±2.8 0.21±0.02 6.3±1.1
15 2000, 0.6 0.1 205.9±9.0 -41.7±11.1 0.99±0.21 5.94±1.0
16 2000, 1 0.1 288.6±12.5 -27.3±6.6 1.01±0.58 10.10±1.25
17 1250, 0.6 0.1 218.0±15.5 -36.0±7.5 1.03±0.07 6.18±0.47
18 530, 0.6 0.1 121.6±24.7 -40.6±6.0 0.32±0.10 1.92±0.60
                                                                                            Dox
19 2000, 0.6 0.02 174.5±18.4 -51.1±2.7 0.68±0.09 20.4±3.0
20 2000, 0.6 0.1 225.3±17.5 -43.0±10.3 2.50±0.18 15.0±1.1
21 2000, 0.6 0.2 274.6±10 -42.3±8.9 6.8±0.85  20.4±2.56
                                                       
         Size, zeta potential, DL and EE of NPs prepared by different formulations (n=3). The solvent and non-solvent type, S/NS ratio 
and the PVA Mw and concentration, were the same as formulation 8 in table 2.
Formulation No. Time: 0 4 hrs 1 week
12 117.3±10.1 121.8±4.6 118.1±18.5
10 176.0±7.2 175±3.2 164.0±7.1
6 204.3±11.7 181.1±4.9 148.3±5.0
7 197.0±4.3 174.2±17.2 149.1±9.3
8 173.0±7.8 168.9±5.2 162.9±31.1
22 306.0±7.3 247.4±17.6 185.0 ±9.2
15 205.9 ±9.0 210.1±8.8 204.0 ±7.1
20 225.3±17.5 211.9±2.7 259.6±11.7
Formulation 22 was the same as formulation 8 but the concentration of PCLF in acetone was 2.5 w/w%.
         Size of NPs suspension of different formulations (in DW) after 0, 4 hrs and 1 week of preparation (n=3)
according to the report (29) might be related to the 
large surface area of the NPs and the high water 
solubility of drugs accelerate drug loss into the water 
                                                      
was found in DL and EE between NPs prepared 
from PCLF2000 and 1250 (formulation 15 and 17) 
(p>0.05). However, the DL and EE related to the NPs 
prepared by PCLF530 (formulation 18) were small 
                                                    
                                                   
lower Mw. When PCLF2000 concentration was 
increased from 0.6 to 1% w/v, the EE increased to 
10% (formulations 15 and 16).
PCLF NPs suspended in DW, were stable even after 
                                                 
                                                  
rpm) for 30 minutes was required. NP suspension 
showed almost no change in size for one week 
without considerable precipitate or aggregation 
especially when the drug was loaded (Table 5) 
and even after 6 months most of the NPs were still 
stable as suspension due to the surface charge of the 
NPs which is also reported previously (31). PBS 
accelerated NPs precipitation probably because of 
ion interactions on the surface charge.
The in vitro release (Fig 11) showed an initial burst 
                                                       
release of the drug distributed close to the surface 
of the NPs. The release rate of Dox was shown to 
be more than Trb as 80% were released during 3 
and 4 days respectively which may be related to the 
drug diffusion through the polymeric matrix (32) 
indicating the high inhibitory effect of the PCLF 
against release of the drug (29). Moreover, such 
sustained release could be attributed to the slow 
degradation of PCLF (13). 
In summary very stable Dox loaded NPs with 
a size range of 174.5±18.4 to 344.5±31.7 nm Shokri et al / DARU 2011 19 (1) 12-22 21
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Doxorubicin HCl
                                                 
nanoprecipitation method for NPs of different 
purposes. NPs could sustain drug release, owing to 
PCLF matrix and PCLF slow degradation. Although 
PCLF530 NPs were the smallest, they had lower DL 
than PCLF1250 and 2000 NPs. 
                                                                                                                                    
size of NPs prepared in the presence of PVA22000 in DW phase (0.3w/v%) and   shows the size of NPs prepared without PVA (n=3).
                                                                                                                                        
shown as cumulative percent of released drug and as mean ± SD (n=3).
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